DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)
Delve into the cutting-edge advancements presented at ACC 2025 in Chicago through these focused video briefs from leading cardiologists as they dissect the latest clinical trial data surrounding emerging non-steroidal mineralocorticoid receptor antagonist therapy.
Episodes 1-7 of 7
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
CME/CEExpert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
CardiologyAnalysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
CardiologyEffect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
CardiologyKidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
CardiologyMode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
- advertisement
NYHA FC and Finerenone Response: Clinical Trial Insights
CardiologyNYHA FC and Finerenone Response: Clinical Trial Insights
